2019
Chapter 13 Trauma and Addiction—How to Treat Co-occurring PTSD and Substance Use Disorders
Vojvoda D, Petrakis I. Chapter 13 Trauma and Addiction—How to Treat Co-occurring PTSD and Substance Use Disorders. 2019, 189-196. DOI: 10.1016/b978-0-323-54856-4.00013-4.Peer-Reviewed Original ResearchSubstance use disordersAlcohol use disorderPosttraumatic stress disorderComorbid substance use disorderPTSD symptomsCo-occurring posttraumatic stress disorderRandomized clinical studyWorse clinical outcomesTreatment of patientsSeverity of AUDSeverity of symptomsCo-occurring disordersReduction of severityRecent pharmacological advancesAnticonvulsant topiramateClinical outcomesPharmacological treatmentPTSD comorbidityClinical studiesPharmacological advancesInconstant effectsMedicationsUse disordersAlcohol consumptionN-acetylcysteine
1999
NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders
Krystal J, D'Souza C, Petrakis I, Belger A, Berman R, Charney D, AbiSaab W, Madonick S. NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders. Harvard Review Of Psychiatry 1999, 7: 125-143. PMID: 10483932, DOI: 10.3109/hrp.7.3.125.Peer-Reviewed Original ResearchConceptsN-methyl-D-aspartate (NMDA) subclassChronic pain syndromePain syndromeGlutamatergic dysfunctionNMDA agonistClinical studiesMajor depressionNMDA antagonistsGlutamate receptorsCoagonist siteParkinson's diseaseHuman psychopharmacological studiesPartial agonistAlzheimer's diseaseNeuropsychiatric conditionsNeuropsychiatric disordersDiseasePsychopharmacological studiesAnxiety disordersHuntington's diseaseAgonistsAntagonistTherapeutic hypothesesDisordersAddiction disorders